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Abstract
Background: Patients with ankylosing spondylitis (AS) are 
substantial users of healthcare resources due to chronic and 
potentially disabling disease. This study assessed the impact 
of adalimumab on clinical outcomes, healthcare resource 
utilization, and sick leave in patients with AS in five Central and 
Eastern Europe (CEE) countries.
Methods: This was an observational study in the routine clinical 
setting. Patients diagnosed with AS and starting treatment 
with originator adalimumab were followed for 12 months by 
assessing disease activity (Bath Ankylosing Spondylitis Disease 
Activity Index [BASDAI] and Ankylosing Spondylitis Disease 
Activity Score [ASDAS]) and physical function (Bath Ankylosing 
Spondylitis Functional Index [BASFI]). Data on healthcare 
resource utilization and sick leave were collected prospectively 
and compared with historical data before adalimumab initiation, 
as well as between treatment responders and non-responders 
defined by BASDAI-50.
Results: The total effectiveness population comprised 450 
patients with on average long-standing AS, high disease activity, 
and functional impairment. At 12 months of adalimumab 
therapy, mean ASDAS and BASFI scores were in the range of low 
disease activity and normal physical function, respectively. The 
mean number of hospital admissions, hospital inpatient days, 
and healthcare provider visits were decreased by 67.9, 83.0, and 
46.3%, respectively. The number and length of sick leaves were 
decreased by 65.6 and 81.4%, respectively. Reductions were 
higher in treatment responders than non-responders.
Conclusion: Originator adalimumab in routine clinical 
practice in five CEE countries produced clinically meaningful 
improvements in disease activity and physical function, and it 
was associated with reductions in healthcare resource utilization 
and sick leave.
Keywords: adalimumab, ankylosing spondylitis, disease 
activity, healthcare resource utilization, physical function, work 
outcomes.
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Introduction
Ankylosing spondylitis (AS) is the prototype of axial 
spondyloarthritis (SpA),1,2 characterized by advanced structural 
changes in the sacroiliac joints, which, together with persistent 
inflammatory disease activity and progressive structural 
damage in the spine, can lead to severe functional disability. 
Inflammation may also affect peripheral joints and entheses, 
and extra-articular manifestations (EAMs) such as uveitis, 
inflammatory bowel disease, and psoriasis are frequently 
present.3,4 Similar to individuals with other inflammatory 
musculoskeletal disorders, AS patients have a reduced health-
related quality of life (HRQoL) compared with the general 
population.5
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Due to the chronic, disabling nature of the disease and 
average young age at onset, AS is associated with substantial 
direct medical and indirect societal costs.6,7 AS patients are 
substantial users of disease-related healthcare resources, with 
higher disease activity and worse physical functioning being 
major determinants of these costs.6,7 Moreover, patients with 
AS have significant sick leave and may experience reduced 
productivity while at work due to limitations imposed by 
impaired physical functioning.7–9 Thus, interventions that 
maintain or improve patients’ functional ability have the 
greatest potential to reduce the total costs of the disease.9
Originator adalimumab (HUMIRA®; AbbVie Inc., North Chicago, 
IL, USA) is a fully human anti-tumour necrosis factor (TNF) 
monoclonal antibody that effectively reduces the long-term 
signs and symptoms of AS,10–14 and EAMs such as uveitis 
flares.14 Treatment with adalimumab has also been shown to 
improve patients’ HRQoL and work outcomes such as work 
productivity,13,15–18 and it was cost effective based on a UK 
health economic assessment.19 However, health economic data 
cannot be generalized across countries due to differences in 
healthcare systems and health insurance schemes. At present, 
there is limited available evidence on clinical effectiveness 
and health economic outcomes in patients with AS treated 
with adalimumab in the routine clinical setting in Central 
and Eastern Europe (CEE). This 1-year observational study 
was undertaken to evaluate the effectiveness and safety of 
adalimumab in routine clinical practice in CEE and to obtain 
region-specific data on the impact of adalimumab therapy on 
healthcare resource utilization, sick leave, and work status.
Methods
Study design and population
This observational study was performed in a multi-country, multi-
centre, single-arm format in five CEE countries (Croatia, Czech 
Republic, Hungary, Romania, and Russia) between October 2012 
and October 2014. The study was approved by the local ethics 
committees of the participating countries according to local 
laws and regulations. The study was conducted according to 
the Declaration of Helsinki for all human or animal experimental 
investigations. The study is registered at ClinicalTrials.gov 
(ClinicalTrials.gov identifier NCT01754727).20
Patients older than 18 years with active AS and fulfilling the 
modified New York Criteria21 were eligible for the study. All 
patients were assigned treatment with originator adalimumab 
(hereafter referred to as adalimumab) and were prescribed 
adalimumab for ≤1 month before study enrolment and 
independent of study inclusion. A negative screening test result 
for tuberculosis (TB) or TB prophylaxis as per local guidelines 
was required. Patients had to be willing to authorize the use 
and disclosure of personal and health data and to provide 
written informed consent to participate in the study.
Patients were treated with adalimumab 40 mg subcutaneously 
every other week throughout the 12-month follow-up period. 
Patients with dose modifications were not excluded from the 
study per protocol. Assessments were performed at enrolment 
(baseline) and then prospectively at 3 (Visit 1), 6 (Visit 2), 9 (Visit 3), 
and 12 (Visit 4) months of treatment, though the actual number 
and timing of follow-up visits were at the investigator’s 
discretion. In the event of premature discontinuation of 
adalimumab treatment before study end, the patient’s next 
routine follow-up visit was the study termination visit.
Assessments
Patient sociodemographic characteristics and AS-specific 
medical history were recorded at baseline.
Disease activity was assessed using the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) and Ankylosing 
Spondylitis Disease Activity Score (ASDAS). BASDAI scores 
range on a numerical scale from 0 (no symptoms) to 10 (very 
severe symptoms).22 Treatment response was defined as a 
50% reduction from baseline in the BASDAI score,22 and it is 
expressed as BASDAI-50 response. Remission (inactive disease) 
was defined as ASDAS score <1.3; low disease activity by scores 
between 1.3 and <2.1; high disease activity by scores between 
2.1 and 3.5; and very high disease activity by scores >3.5. 
Clinically important improvement was defined as an ASDAS 
change of ≥1.1 units, and major improvement was defined as 
a change of ≥2.0 units.23,24 Functionality was measured by the 
Bath Ankylosing Spondylitis Functional Index (BASFI) score on a 
numerical scale from 0 to 10.22
Data on AS-related healthcare resource utilization and sick 
leave during treatment with adalimumab were recorded 
prospectively by a systematic interview with the patient at each 
study visit. The number of admissions to hospital, number of 
hospital inpatient days, number of visits to various healthcare 
providers (e.g. general practitioner, rheumatologist, other 
specialists, physiotherapist, and rheumatology nurse), number 
of episodes of sick leave, and number of sick leave days were 
recorded. These same data on AS-related healthcare resource 
utilization and sick leave in the 3-month period preceding the 
start of adalimumab therapy were also recorded at baseline. 
Retrospective data were collected by medical chart review and 
supplemented by patient interview. The 3-month data were 
multiplied by a factor of 4 for comparison with the prospective 
12-month data collected during adalimumab therapy. This 
approach was used to limit memory bias.25,26
Changes in healthcare resource utilization and sick leave in the  
12 months before and after the start of adalimumab treatment 
were compared between treatment responders and non-
responders defined by achieving or not achieving a BASDAI-50 
response.
At each visit, data on AS-specific systemic medication and 
information on work status were also recorded. Serious adverse 
events (SAEs) were reported based on the Medical Dictionary 
for Regulatory Activities (version 18.1, English) system organ 
class and preferred term.
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were employed full-time, 10% (n=45) were retired, and 18.2% 
(n=82) were unemployed due to disability, mainly relating to 
AS. AS-related EAMs (past or present) at the time of enrolment 
included uveitis (n=86; 19.1%), inflammatory bowel disease 
(n=42; 9.3%), and psoriasis (n=29; 6.4%); 38.9% of patients 
(n=175) had peripheral arthritis. Previous use of conventional 
synthetic disease-modifying antirheumatic drugs (csDMARD) or 
biological DMARD (bDMARD) medications was documented for 
42.9% of patients (n=193). The most frequently used csDMARD 
was sulfasalazine (n=127; 28.2%), and 14.2% of patients had 
previously been exposed to bDMARDs (etanercept, infliximab, 
or golimumab). At study inclusion, 293 patients (65.1%) were 
receiving AS-specific medications, mainly non-steroidal anti-
inflammatory agents (NSAIDs), including cyclo-oxygenase-2 
(COX-2) inhibitors (n=214; 47.6%), and 82 patients (18.2%) were 
taking sulfasalazine. Baseline BASDAI (6.3±2.1), ASDAS (4.0±1.1), 
and BASFI (6.2±2.3) scores indicated high levels of disease 
activity and functional impairment.
Improvements in disease activity, 
physical function, and work status during 
adalimumab treatment
Remarkable improvements in disease activity and physical 
function were observed by the first visit at 3 months, followed 
Statistical analyses
Statistical analyses were conducted using SAS® version 
9.2 (SAS Institute, Cary, NC, USA). The total effectiveness 
population consists of all patients who received at least 
one dose of adalimumab in the course of the study. In this 
observational study, no hypothesis testing was performed; 
results are summarized by descriptive statistics. Continuous 
parameters are described as mean ± standard deviation (SD). 
Categorical data are described using absolute and relative 
(%) frequency distributions. For assessments over time, the 
observed case analysis by visit (Visits 1 to 4) is used. For 
disease activity and functionality measures, the observed 
case analysis is complemented by an analysis according to the 
last observation carried forward (LOCF) principle at final visit 
(Visit 4). The last evaluable score was used for the analysis, and 
the respective value for the corresponding visit is expressed as 
Visit 4-LOCF. A descriptive subgroup analysis was performed 
to compare the results of healthcare resource utilization and 
sick leaves stratified by treatment response (as defined by 
BASDAI-50 response). The study was not powered for statistical 
comparison between subgroups.
Results
Patient disposition
A total of 452 patients were enrolled in the study: 148 (32.7%) 
in Hungary, 121 (26.8%) in Romania, 90 (19.9%) in Russia, 62 
(13.7%) in the Czech Republic, and 31 (6.9%) in Croatia. As two 
enrolled patients did not receive adalimumab treatment, the 
total effectiveness population comprised 450 patients.
In total, 109 patients dropped out of the study before study 
end. For 87 of these patients, reasons for study discontinuation 
were investigator decision (n=49), lost to follow-up (n=15), 
patient request (n=11), adverse event (n=11), and SAE (n=1). 
The remaining 22 patients were lost to follow-up without a 
documented reason.
Mean study follow-up was 318.3±102.3 days.
Almost all patients with valid data (>98.4%) received adalimumab 
at the recommended dose of 40 mg subcutaneously every other 
week over the study course. During the 12-month observational 
period, eight patients had one dosage change and four patients 
had two dosage changes. The proportion of patients who 
received 40 mg every week was 0.7% (n=3, Visit 0), 0.7% (n=3,  
Visit 1), 0.5% (n=2, Visit 2), 1.1% (n=4, Visit 3), and 0.3% (n=1, Visit 4).
Baseline demographics and clinical 
characteristics
The baseline demographic and clinical characteristics of 
the 450 patients in the total effectiveness population are 
summarized in Table 1. Mean age ± SD was 42.9±12.1 years, and 
68.7% of patients were men. Mean duration from diagnosis 
was 7.7±8.7 years. At study inclusion, 62.7% of patients (n=282) 
Table 1. Baseline demographics and clinical 
characteristics of patients in the total 
effectiveness population (n=450).
Characteristics Value
Age (years), mean ± SD 42.9±12.1
Male:female ratio, n (%) 309 (68.7%):141 (31.3%)
Time from AS diagnosis 
(years), mean ± SD
7.7±8.7
Positive TB screening, n (%) 37 (8.2)
Working full-time (paid), n (%) 282 (62.7)
Peripheral arthritis, n (%) 175 (38.9)
Extra-articular manifestations, 
n (%)
 Uveitis
  Inflammatory bowel 
disease
 Psoriasis 
86 (19.1)
42 (9.3)
29 (6.4)
BASDAI (0–10), mean ± SD 6.3±2.1
ASDAS, mean ± SD 4.0±1.1
BASFI (0–10), mean ± SD 6.2±2.3
AS, ankylosing spondylitis; ASDAS, Ankylosing 
Spondylitis Disease Activity Score; BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI, 
Bath Ankylosing Spondylitis Functional Index; SD, 
standard deviation; TB, tuberculosis.
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by more gradual but continued improvements through to 
study end. Mean ± SD BASDAI, ASDAS, and BASFI scores at the 
last study visit as observed were 2.0±1.6, 1.7±1.0, and 2.3±2.0, 
respectively (Figure 1). Compared with baseline, BASDAI-50 
response was achieved by 78.9% of patients at study end, and 
ASDAS major improvement was shown by 64.8% of patients 
(observed data).
The proportion of patients actively working for payment during 
the study increased slightly from 62.7% at baseline (n=282) to 
67.6% at month 12 (n=244).
Reduction in healthcare resource utilization 
and sick leave
Improvements were observed across all parameters used to 
compare healthcare resource utilization before and after the 
start of adalimumab treatment.
Reductions by study end (12-month visit) versus the 12-month 
period prior to adalimumab therapy were as follows (all observed 
data): mean number of hospital admissions from 2.8±3.9 (n=404) 
to 0.9±2.8 (n=392), a decrease of 67.9%; mean number of inpatient 
days from 23.0±40.8 (n=395) to 3.9±17.7 (n=388), a decrease 
of 83.0%; mean number of visits to healthcare providers from 
25.7±22.8 (n=422) to 13.8±11.3 (n=411), a decrease of 46.3%, 
which was mainly due to fewer visits to rheumatologists  
(−4.4 visits) and general practitioners (−4.3 visits).
Data on sick leave were analysed for employed patients 
(i.e. those with a ‘working for payment’ status at baseline 
and at least once during follow-up). Reductions by study 
end (12-month visit) versus the 12-month period prior to 
adalimumab therapy were as follows (all observed data): mean 
number of sick leave episodes from 3.2±8.8 (n=246) to 1.1±5.6 
(n=249), a decrease of 65.6%; mean number of sick leave days 
from 32.2±69.2 (n=243) to 5.1±24.5 (n=249), a decrease of 81.4%.
In a subgroup analysis stratified by the BASDAI-50 treatment 
response, reductions in the numbers of hospital admissions, 
inpatient days, sick leave episodes, and sick leave days were 
numerically larger in treatment responders compared with 
treatment non-responders; the only parameter showing no 
difference was the number of visits to various healthcare 
providers (Table 2).
Safety outcomes
A total of 29 SAEs, most frequently infections and infestations, 
were reported in 19 patients (4.2% of the effectiveness 
Figure 1. Disease activity and physical functioning at baseline, month 3 
(Visit 1), month 6 (Visit 2), month 9 (Visit 3), month 12 (Visit 4), 
and month 12 LOCF (Visit 4-LOCF).
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population); 27 of these events (93.1%) were classified as mild or 
moderate in severity. Seventeen SAEs (58.6% of the total SAEs) 
were considered to be related to adalimumab with reasonable 
possibility; the remaining events were assessed as unrelated. 
All events were within the scope of the known safety profile of 
adalimumab. No new safety signals were detected.
Discussion
As treatment with bDMARDs is considerably more expensive 
than that with conventional systemic agents, reductions in 
the utilization of healthcare resources as well as benefits in 
functional status and work productivity outcomes are of 
particular socioeconomic interest.
In this cohort of patients with AS from five participating CEE 
countries, marked improvements were observed in clinical 
disease activity and physical function under adalimumab 
therapy, as well as decreases in healthcare resource utilization 
and number of sick leave episodes and sick leave days, 
compared with the period prior to starting adalimumab 
therapy. These findings are consistent with other studies 
reporting reductions in hospital admissions and sick leave in 
AS patients during treatment with anti-TNF agents.27–29 As 
shown previously with infliximab, cost savings generated by 
fewer hospital admissions and sick leave days can contribute 
substantially towards reducing the direct and indirect costs 
of AS,27 offering a range of benefits for healthcare systems, 
employers, and patients. Moreover, economic assessments 
conducted in the UK showed that adalimumab19 and other anti-
TNF agents30 were cost effective compared with conventional 
therapy for treating patients with AS and non-radiographic 
axial SpA.
Reductions in the various parameters of healthcare resource 
utilizations were considerable in our study, especially for 
number of sick leave days. Despite the relatively short 
observational period of 12 months, an increase in the 
proportion of patients who could work for payment was 
also noted. These findings are in line with the sizeable 
improvements observed in clinical outcomes: despite the 
lengthy average disease duration, at the end of the study, 
mean ASDAS was in the range of low disease activity (<2.1)23 
and mean BASFI was in the range of normal physical function 
(<3.0).31,32 It has been shown previously that the capability 
of AS patients to work correlates directly with the physical 
consequences associated with their condition.33,34 Further, 
even though improvements with adalimumab therapy were 
observed amongst both responders and non-responders as 
defined by the BASDAI-50 response, it was shown clearly in 
our study that reductions in healthcare resource utilization 
were much larger amongst clinical responders. The only 
parameter showing no difference between responders and 
non-responders was the number of outpatient visits. A possible 
explanation for this finding may be that the majority of 
patients, irrespective of the main clinical disease activity, may 
have had comorbidities requiring regular medical checks.
Specific measures to assess workability, such as the Work 
Productivity and Activity Impairment-Specific Health Problem 
Questionnaire (WPAI-SHP),33 were not employed in our study. In 
a previous observational study of adalimumab in CEE countries, 
presenteeism (percentage of impairment while working) 
decreased from 56.7 to 20.1%, absenteeism (percentage of 
work time missed) decreased from 15.6 to 6.4%, and total work 
productivity impairment decreased from 59.9 to 22.1% during 
treatment for 1 year.18
In general, the data presented in this study agree with previous 
global10–14 and regional18 clinical trials investigating the 
effectiveness, cost-effectiveness,19 and safety35 of adalimumab 
in AS. No new safety findings were identified outside of the 
well-established safety profile of adalimumab.35
The study is limited by its observational design, which provides 
a lower level of evidence than randomized controlled trials; 
however, real-world data better reflect the standard of care 
received by patients with AS. As a reasonable proportion of 
patients (65%) were using AS-specific medications in addition 
to adalimumab and there were no restrictions in changing 
concomitant medication, the outcomes observed may not be 
solely attributable to adalimumab. The calculation method and 
retrospective-prospective manner in which patient charts and 
Table 2. Changes in healthcare resource utilization and sick leave in the 12 months before and after the start of 
adalimumab treatment according to treatment response defined by BASDAI-50.
Responders Non-responders
Number of hospital admissions, mean ± SD –2.4±4.5 (n=263) –0.8±4.3 (n=104)
Number of inpatient days, mean ± SD –21.7±38.2 (n=255) –16.0±60.1 (n=101)
Number of visits to different healthcare providers, mean ± SD –11.6±20.8 (n=284) –12.4±26.7 (n=109)
Number of sick leave episodes, mean ± SD –2.6±5.9 (n=173) –0.7±3.4 (n=57)
Number of sick leave days, mean ± SD –29.2±64.7 (n=172) –18.4±66.7 (n=56)
BASDAI-50, ≥50% improvement from baseline in the Bath Ankylosing Spondylitis Disease Activity Index score;  
SD, standard deviation.
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patient interviews were used to determine healthcare resource 
utilization and sick leave may have introduced recall and 
seasonal bias. Lastly, retrospective data for healthcare resource 
utilization and sick leave may have been overestimated by 
extrapolating data reported for the 3 months immediately 
before the start of adalimumab treatment (when disease 
activity may have been higher) across a 12-month period.
Conclusion
Treatment with originator adalimumab in routine clinical 
practice in five participating CEE countries was associated with 
clinically meaningful improvements in disease activity and 
physical function as well as sizeable reductions in healthcare 
resource utilization and sick leave.
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